BMS takes on 'new normal' as it gears up for Eliquis launch
This article was originally published in Scrip
2012 was a year of transition for Bristol-Myers Squibb, which saw it turn the patent cliff into a "much reduced patent slope", according to CEO Lamberto Andreotti, who was speaking at the JP Morgan global healthcare conference on 8 January.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.